We found that THBS1 was lower expressed in the serum of AML patients, and the reason for low THBS1 in serum was also discussed preliminarily; through MSP and GEO datasets, we found that compared with healthy control, THBS1 methylation rate was higher, and hypomethylating agent treatment could lead to up-regulation of THBS1 expression and reduction of methylation level. This evidence concerns the gene THBS1 and acute myeloid leukemia.